RELATIVITY-022 study design. ∗Part A dose-escalation cohort includes patients with R/R CLL, HL, certain non-HLs, and MM. The 800-mg dose was stopped because of futility. †Part C dose-escalation cohort includes patients with R/R HL and DLBCL. ‡Part B cohort expansion included patients with R/R disease. §Patients with PD-(L)1–progressed HL had disease progression while on, or within 3 months of, treatment with an anti–PD-(L)1 as their most recent therapy. ¶Most patients had classic HL; 2 patients with nodular lymphocyte–predominant HL were included in part D (1 in PD-(L)1–progressed and 1 in PD-(L)1–naive). CLL, chronic lymphocytic leukemia; IL, indolent lymphoma; MM, multiple myeloma.